1. Home
  2. TECX vs INBX Comparison

TECX vs INBX Comparison

Compare TECX & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$18.42

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$76.74

Market Cap

430.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
INBX
Founded
2019
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
359.0M
430.2M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
TECX
INBX
Price
$18.42
$76.74
Analyst Decision
Strong Buy
Hold
Analyst Count
5
2
Target Price
$81.20
N/A
AVG Volume (30 Days)
301.7K
236.0K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,400,000.00
Revenue This Year
N/A
$563.00
Revenue Next Year
N/A
$230.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.70
$10.81
52 Week High
$61.07
$94.47

Technical Indicators

Market Signals
Indicator
TECX
INBX
Relative Strength Index (RSI) 45.34 46.07
Support Level $18.60 $79.00
Resistance Level $20.62 $94.47
Average True Range (ATR) 1.46 5.90
MACD -0.22 -2.08
Stochastic Oscillator 5.03 5.29

Price Performance

Historical Comparison
TECX
INBX

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: